Company intelligence / Profile preview
Nanjing NeuroDawn Pharmaceutical
Nanjing, Jiangsu, 中国（China）neurondawn.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Nanjing NeuroDawn Pharmaceutical is developing small molecule and chemical drugs for central nervous system diseases, with lead programs in acute ischemic stroke at the NDA/BLA stage and several others in Phase 3 clinical trials targeting neurological and psychiatric disorders[7].
- Therapeutic areas
- OncologyPsychiatryCardiovascularNeurology
- Modalities
- Small moleculeChemical drug
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Nanjing NeuroDawn Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nanjing NeuroDawn Pharmaceutical.